How does a fractional CRO build a revenue engine for a healthcare technology company?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.

👉 See Kory White on LinkedIn

The Buying Committee: Four Distinct Roles with Conflicting Priorities

The buying committee for healthcare technology is rarely smaller than six people and often grows to twelve or more for deals above $150,000 in annual contract value. The clinical champion is typically a department head - a chief medical officer, nursing director, or lab director - who identifies the workflow pain and drives initial interest. This person cares about time savings, error reduction, and patient outcomes, but they have no budget authority. The IT security officer evaluates data encryption, HIPAA compliance, SOC 2 Type II reports, and integration with existing EHR systems like Epic or Cerner. This role can kill a deal in a week if your penetration test reveals a vulnerability, regardless of clinical value. The legal and compliance team reviews business associate agreements, subcontractor clauses, indemnification terms, and breach notification procedures - a process that takes 60-90 days minimum and often requires redlines on standard terms. The procurement and finance team demands proof of ROI, references from similar-sized health systems, and pricing that aligns with their budget cycle - typically approved in April for an October start.

Deal size for healthcare technology ranges from $50,000 to $500,000 in ACV for point solutions, but enterprise platform deals can exceed $1 million with implementation fees. The shape is almost always a pilot or phased rollout: a 3-6 month proof of concept with a single department, followed by a system-wide expansion if the pilot meets clinical and operational metrics. Budget approval requires a formal business case presented to a steering committee that includes the CFO, CMO, and CIO - meaning the fractional CRO must equip the clinical champion with a slide deck that quantifies ROI in terms of reduced readmissions, faster discharge times, or fewer adverse events. Deals stall most often at two points: the integration assessment, where IT discovers your API doesn't handle their HL7 v2.5 format, and the legal review, where your standard terms don't match their required 90-day termination notice or unlimited liability cap.

Sales-Cycle Implications: The Motion is Consultative, Not Transactional

The sales cycle forces a consultative motion because no healthcare technology product sells itself - the clinical champion needs to be educated on how your solution fits into their existing workflow, and the IT team needs technical validation that your product won't cause a data breach. Ramp time for a new sales hire in this market is 6-9 months before they hit quota, because they must learn the regulatory landscape, the EHR integration nuances, and the buying committee dynamics for each specific health system. Forecast behavior is unreliable in quarters one and two of a tenure, because deals that look 70% likely in week six can drop to 20% when the IT security team requests a third-party penetration test that takes eight weeks.

Pipeline shape is top-heavy and slow-moving. A typical healthcare technology pipeline has 3-5x the dollar value of the target in early-stage opportunities, because conversion rates are low - 15-20% from initial meeting to signed contract. The leaks are predictable: 30% of opportunities die at the IT security review because the vendor cannot provide a completed HITRUST assessment or SOC 2 report. Another 25% stall indefinitely at legal because the vendor refuses to accept the health system's business associate agreement template. 15% die at the pilot stage because the clinical champion changes jobs or the department budget gets frozen mid-year. The remaining 30% close, but with an average sales cycle of 11 months from first contact to signature.

The fractional CRO must build a pipeline that accounts for these leaks by forcing early-stage qualification on compliance readiness. Every opportunity that enters stage one must have a completed security questionnaire and a redlined BAA template before the first demo. This is counterintuitive to most SaaS playbooks, which prioritize product demos first, but in healthcare, the IT gatekeepers will kill a deal faster than the clinical champion can revive it. The fractional CRO also needs to build a forecasting model that weights deals by stage and compliance status, not just by sales rep confidence. A deal at 70% confidence with a signed BAA and completed integration test is more predictable than a deal at 90% confidence with a pending legal review.

The First 90 Days: Audit, Triage, and Establish Compliance Infrastructure

The fractional CRO's first 90 days in a healthcare technology company are about auditing the existing revenue engine for compliance readiness, not just sales velocity. Week one through four: conduct a compliance audit of every active deal in the pipeline. Map each opportunity to the specific health system's procurement requirements - do they require a HITRUST assessment? A SOC 2 Type II report? A completed CAQH CORE credentialing form? Identify which deals are stalled because the company lacks the documentation to pass IT security review. Week five through eight: triage the pipeline by compliance status. Move resources to the deals that have the highest probability of closing based on regulatory readiness, not just deal size or relationship strength. Kill deals where the health system's IT requirements exceed the company's current compliance posture - for example, if the company only has SOC 2 Type I but the buyer demands Type II, the deal will die in six months anyway.

Week nine through twelve: establish the operating cadence for compliance-first revenue operations. This means creating a standardized security questionnaire response library, a pre-approved BAA template, and a integration validation checklist that the sales team uses before any demo. The fractional CRO must also build a deal review process that includes a compliance gate at each stage - no opportunity moves from stage two to stage three without a signed NDA and a completed security questionnaire. This is the operating cadence: weekly pipeline reviews that focus on compliance milestones, not just revenue milestones. Monthly executive reviews that track the number of deals that passed IT security review, not just the number of demos completed. Quarterly business reviews that assess whether the company's compliance posture is improving fast enough to match the health systems' requirements.

The fractional CRO owns the revenue engine design, the sales process, the forecasting methodology, and the compliance infrastructure. They advise on product roadmap prioritization based on buyer requirements - for example, if every health system asks for single sign-on with SAML 2.0, the fractional CRO pushes that feature to the top of the product team's backlog. They also advise on pricing strategy, specifically how to structure pilot-to-expansion pricing that aligns with health system budget cycles. The signal to convert to full-time is when the company has 10+ active enterprise opportunities that require ongoing executive-level relationship management with health system C-suite buyers. The signal to stay fractional is when the company still needs the compliance infrastructure buildout more than the ongoing account management - because a full-time CRO will be pulled into day-to-day sales management and lose focus on the regulatory scaffolding that the company still lacks.

Building the Pipeline: Referral-Driven, Not Inbound-First

Healthcare technology pipeline cannot be built through inbound marketing alone because clinical champions do not search Google for "workflow automation software" - they learn about new tools through peer networks at medical conferences, trade association meetings, and advisory board discussions. The fractional CRO must design a pipeline that is 70% referral-driven and 30% outbound, with zero reliance on cold email blasts or LinkedIn spam. The referral motion requires identifying 10-15 key opinion leaders in the target clinical domain - for example, if the product is for emergency department workflow, the KOLs are the medical directors of the busiest EDs in the country. The fractional CRO builds relationships with these KOLs through advisory board participation, sponsored research, or co-authored white papers. Each KOL becomes a reference account that generates 2-3 qualified referrals per quarter.

Outbound motion is targeted account-based sales development, not volume-based. The SDR team researches 50 target health systems based on criteria like bed size, EHR vendor, and existing technology stack. For each account, the SDR identifies the clinical champion by scanning LinkedIn for the department head who has posted about workflow challenges or attended relevant conferences. The outreach is a personalized email referencing a specific challenge the health system has publicly discussed - for example, "I saw your health system's recent quality report on reducing door-to-balloon time for STEMI patients. Our platform has helped three similar-sized systems reduce that time by 18%." The conversion rate on this motion is 5-8% to a first meeting, which is double what generic cold outreach achieves.

Pipeline shape in healthcare technology is a funnel that narrows sharply at the IT security stage. The fractional CRO must build a pipeline that has 3-4x the number of opportunities at the top compared to what a typical SaaS company would need, because the conversion rate is lower. For a $5 million annual revenue target, the pipeline needs $20-25 million in early-stage opportunities, not the $10-15 million that a B2B SaaS company with a 6-month sales cycle would require. The leaks are not in the discovery or demo stages - they are in the security review and legal stages, where deals that look 80% likely suddenly drop to 0% because the health system's IT team finds a gap in the vendor's data encryption protocol.

The Revenue Leader Profile: Operator, Not Strategist

The fractional CRO for a healthcare technology company must be an operator who has personally sold into health systems, not a strategist who has only managed enterprise sales teams in adjacent industries. The first 90 days are not about creating a five-year strategic plan - they are about fixing the compliance infrastructure, re-qualifying the existing pipeline, and closing the 2-3 deals that are stalled at legal. The operating cadence is weekly pipeline reviews that focus on compliance milestones: which deals have submitted their security questionnaire? Which deals have a signed BAA? Which deals have completed integration testing? The fractional CRO does not attend every sales call - they attend the ones where the health system's CIO or CMO is present, because those relationships require executive-level credibility.

The fractional CRO owns the revenue engine design, the sales process, the forecasting methodology, and the compliance infrastructure. They advise on product roadmap prioritization based on buyer requirements - for example, if every health system asks for single sign-on with SAML 2.0, the fractional CRO pushes that feature to the top of the product team's backlog. They also advise on pricing strategy, specifically how to structure pilot-to-expansion pricing that aligns with health system budget cycles. The signal to convert to full-time is when the company has 10+ active enterprise opportunities that require ongoing executive-level relationship management with health system C-suite buyers. The signal to stay fractional is when the company still needs the compliance infrastructure buildout more than the ongoing account management - because a full-time CRO will be pulled into day-to-day sales management and lose focus on the regulatory scaffolding that the company still lacks.

The Operating Cadence: Weekly, Monthly, Quarterly Rhythms

The weekly rhythm is a 60-minute pipeline review that starts with compliance status, not revenue status. Each deal is reviewed against a checklist: security questionnaire submitted, penetration test completed, BAA signed, integration test passed, legal review initiated. Deals that are missing any of these milestones are flagged as at-risk, regardless of the sales rep's confidence level. The monthly rhythm is a business review with the CEO and product team that focuses on two metrics: the number of deals that passed IT security review in the last 30 days, and the average time from first meeting to BAA signature. The quarterly rhythm is a strategic review that assesses whether the company's compliance posture is meeting the market's requirements - for example, if the company still only has SOC 2 Type I but 80% of health systems now require Type II, the fractional CRO must recommend a budget and timeline for the Type II audit.

The fractional CRO also establishes a monthly "deal doctor" review where the sales team brings the three most stuck deals and the fractional CRO diagnoses the bottleneck. Is it a clinical champion who has lost internal sponsorship? Is it an IT security team that has not received the penetration test report? Is it a legal team that is stuck on a single contract clause? The fractional CRO then assigns specific actions to unstick each deal - for the clinical champion issue, the fractional CRO might arrange a call with a reference customer who faced the same internal resistance. For the IT security issue, the fractional CRO might escalate to the company's CTO to provide a technical deep dive. For the legal issue, the fractional CRO might authorize a one-time exception to the standard contract terms if the deal size justifies the risk.

FAQ

How do you handle a health system that demands a 90-day termination-for-convenience clause? That clause is standard in most health system contracts and is non-negotiable for any vendor under $10 million in revenue. The fractional CRO should accept it but add a clause that requires 30 days written notice before termination and a pro-rata refund of any prepaid implementation fees. The risk is that the health system terminates after 90 days without paying for the implementation cost - so price the implementation fee as a separate line item that is earned upon delivery, not contingent on the subscription term.

What is the ideal pilot structure for a healthcare technology company? A pilot should be 90 days with a single department, priced at 20-30% of the full annual contract value, with clear success metrics defined before the pilot starts - for example, "reduce the average time from lab order to result by 15 minutes" or "increase the percentage of patients discharged before 11 AM by 10 percentage points." The pilot contract should include a mutual termination clause if the metrics are not met, but also an automatic expansion clause if the metrics are exceeded, with a 15% discount on the full ACV for committing to a system-wide rollout within 60 days of pilot completion.

How do you forecast revenue when deals take 9-14 months to close? You cannot forecast individual deals reliably until they have passed IT security review and legal has signed the BAA. Instead, build a weighted pipeline model based on historical conversion rates by stage, not by rep confidence. For example, if 30% of deals that pass IT security review close within 6 months, then a $500,000 deal at that stage is worth $150,000 in the forecast. Also build a "committed" pipeline category for deals that have a signed BAA and a completed integration test - those have a 60-70% close rate and can be used for quarterly guidance to the board.

What is the biggest mistake fractional CROs make in healthcare technology? The biggest mistake is treating the sales cycle like enterprise SaaS and focusing on product demos and ROI calculators while ignoring the compliance infrastructure. A fractional CRO who spends the first 30 days building a demo sequence instead of a security questionnaire response library will have a pipeline full of deals that stall at IT security review and die at legal. The second biggest mistake is not building relationships with the IT security and legal teams at the target health systems before the deal is in procurement - those relationships take 3-6 months to develop and cannot be rushed when the deal is already in legal review.

Sources